Multiple Myeloma

Celgene Receives Orphan Drug Designation For Revimid

Published in Blood Weekly, November 8th, 2001

Celgene Corp.'s Revimid, the company's lead immunomodulatory drug (IMiD), has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for multiple myeloma. Orphan drug status entitles Celgene to seven years of market exclusivity in multiple myeloma for Revimid following FDA approval.

The IMiDs are novel, small-molecule, orally available analogs of thalidomide that are designed to be more potent and have demonstrated a better safety profile in clinical trials than the parent compound. Celgene's IMiDs have significantly greater immunological activity than thalidomide in in vitro studies. Data published in the Journal of Immunology...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2001-11-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry